For citations:
Besova NS, Titova TA, Artamonova ЕV, Tryakin AA, Stroyakovskiy DL, Perminova EV, Yukalchuk DY, Ponomarenko DM, Belyak NP, Orlova RV, Teletaeva GM, Ratner EY, Mochalova AS, Gordeeva OO, Zhabina AS, Gamayunov SV, Smolin AV, Povyshev AY, Andrievskikh MI, Stilidi IS. Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA trial. Meditsinskiy sovet = Medical Council. 2020;(9):165-174. (In Russ.) https://doi.org/10.21518/2079-701X-2020-9-165-174
Email this article 